Indegene
Other · 2 quarters tracked · source-linked performance and management context.
Latest revenue
₹1,000.5 Cr
verified financial record
Quarters tracked
2
source records in the directory
Delivery assessment
Unscored
No scored management commitments are present yet.
Call date
2026-05-13
latest available source date
Signal trajectory
1 actual quarterCurrent read
Unscored
No scored management commitments are present yet.
Latest source read
What changed this quarter?
Indegene delivered a landmark Q4 FY26 with revenue crossing ₹1,000 crore for the first time, up 32.8% YoY, and full-year revenue of ₹3,515 crore (+23.6% YoY). Growth was driven by strong deal momentum, including a tectonic engagement with the largest customer in Germany and a $10M+ ACV omni-channel win. Adjusted EBITDA margin contracted ~150bps due to planned investments in AI, talent, and acquisitions (Bioarm, Cake), but management expects margins to recover to historical levels by H2 FY27. PAT was impacted by a one-time ₹20.3 crore provision for a US class action settlement. The pipeline entering FY27 is stronger and more diversified, with GenAI solutions gaining traction across commercial and medical segments. Key risk: margin recovery may be delayed if investment intensity persists beyond planned timelines.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Positive
Revenue
₹1,000.5 Cr
Source date
2026-05-13
Across the record
Quarter history.
History modules